A Phase II Randomized Double-Blind Trial of Varenicline for the Treatment of Cocaine Dependence

This is a double-blind placebo-controlled clinical trial (n = 200) of varenicline for the treatment of cocaine dependence that utilizes contingency management to promote treatment attendance. Participants will be randomized (1:1) to receive varenicline (1.0 mg BID) for 12 weeks. Primary outcome measures include biochemically verified cocaine and nicotine use.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Addictive Behavior, Cocaine-Related Disorders, cocaine
• Age: Between 18 Years - 65 Years
• Gender: All